Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CELZ-201 (Creative Medical Technology Holdings, Inc.)
- Development stage
- Unknown
- Lead developer
- Creative Medical Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
CELZ-201 is an investigational allogeneic cell-based therapy composed of Perinatal Tissue Derived Cells (PTDCs), which are harvested from human umbilical cord blood and tissue from a single donor source. Developed by Creative Medical Technology Holdings, the therapy is designed to treat type 1 diabetes mellitus by leveraging the regenerative and immunomodulatory properties of these perinatal cells. CELZ-201 is administered via a single intra-arterial infusion directly into the dorsal pancreatic artery, a novel delivery method intended to place the cells in close proximity to the pancreatic environment. The therapy aims to promote the preservation or restoration of insulin-producing beta cells without the requirement for chronic immunosuppression, utilizing the cells' low antigenicity, self-renewal capabilities, and potential for large-scale clinical expansion.
- Brand names
- AlloStem
- Other names
- AlloStemPerinatal Tissue Derived CellsPTDCsPRDCs
Beyond the preview
Go deeper on CELZ-201 (Creative Medical Technology Holdings, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CELZ-201 (Creative Medical Technology Holdings, Inc.).